The law may have good intentions and does address a serious problem (i.e. counterfeit products with no active medications and/or serious quality control problems) that could cause harm for some consumers. But that may not be the complete story behind the IMPACT changes.

Can you explain how this is true? The definition classifies a product “with a false representation of its identity and/or source” as a counterfeit – or, in more common parlance, a product is counterfeit if it lies about what it is or where it's come from. How does this single out generic anabolic steroids? Do they all have fake packaging?

Also, on the page linked to, comments are made about IMPACT that may be misleading. For example, while patent-holding pharmaceutical firms are involved with IMPACT, as stakeholders, so are generic associations. For example, the European Generic Medicines Association supports IMPACT's definition, and the International Generic Pharmaceuticals Alliance was a founder of IMPACT. Furthermore, IMPACT mainly comprises of national drug regulatory agencies, most of which represent less developed countries (where counterfeit drugs are rife, and claim many lives–up to a third of medicines in some poor countries are fakes).

I simply don't see a “Big Pharma” conspiracy here.